SS-31peptidecycle SS-31, also known as Elamipretide, is a synthetic peptide that has garnered significant attention for its potential to target and improve mitochondrial function. This peptide is designed to accumulate within mitochondria, offering a unique approach to cellular energy restoration and protection. Understanding the appropriate dosing for SS-31 is crucial for individuals exploring its therapeutic potential, and current research and clinical observations provide valuable insights into effective protocols.
The search intent for SS-31 peptide dosing reveals a strong interest in specific dosage amounts and administration schedules.SS-31 Patient Information.docx While there isn't a universally standardized dosage, available information from clinical trials and anecdotal reports offers a spectrum of recommended ranges.作者:MD Campbell·2018·被引用次数:138—Young (5 mo) and aged (26 mo) female C57BL/6Nia mice were treated for 8-weeks with 3 mg/kg/daysS-31. Mitochondrial function was assessed in vivo using31P and ...
Several factors can influence the optimal dose of SS-31Methods: After screening, eligible participants were randomized 1:1 to receive either 24 weeks of elamipretide at adoseof 40 mg/d or placebo subcutaneously.. These include the individual's health status, specific therapeutic goals, and tolerance. For individuals initiating SS-31 therapy, a cautious approach is often recommended.作者:AS Guides—SS-31 Dosage. A dose of 40mg is considered safe and well-tolerable in human subjects. However, it is important to note that the dose may vary ... Some protocols suggest starting with a lower dose, for example, 5 mg daily for Weeks 1–2, to assess individual toleranceSS-31 10mg. This initial phase allows the body to adapt to the peptide before potentially increasing the dosage.
Following this introductory period, a common target dose observed in clinical trials is 10 mg daily. This standard target dose is frequently cited as the most common clinical trial dose, aiming for optimal mitochondrial protection and restoration. For certain applications, 10 mg administered daily is considered the standard therapeutic dose.
However, more recent clinical trial data suggests higher dosages may also be well-tolerated and effective. Based on the most recent clinical trials, the recommended dosing for Elamipretide (SS31) is 40 mg per day administered subcutaneously. This higher range has been explored in human trials, with SubQ doses up to 40mg/day demonstrating good tolerability. It's also noted that the dosage for SS-31 could be upwards of 40mg per day, with the exact amount being dependent on specific individual needs, and a doctor will prescribe accordingly.
The administration of SS-31 can vary. While subcutaneously is a common route, other methods have been explored. For instance, in some research settings, SS31 was administrated for 10 days at dosages of 10 mg/kg per day in animal studies, indicating a focus on daily administration.
Specific protocols might also involve cycling. Some users employ a cycle of SS-31 first, potentially at 4-10mg a day for 20-25 days, before considering other peptides.Dosing Protocol ·Start: 5 mg daily for Weeks 1–2to assess individual tolerance. · Standard Target: 10 mg daily by Week 3 (most common clinical trial dose).
For acute conditions, a lower dose might be considered, such as 2 mg (0.2ml or 20 units) SQ.
In a different dosing schedule, some protocols outline a gradual increase:
* Week 1: 10 units (1mg), 1x/day, 5 days/week
* Weeks 2–5: 20 units (2mg), 1x/day, 5 days/week
* Weeks 6–8: 30 units (3mg), 1x/day, 3 days/week
* Weeks 9–12: 40 units
Another suggested regimen involves 50-100 mcg, 1-2x daily for a minimum duration of 30 days.
Research provides further context for SS-31 peptide dosing. Studies have explored various dosages in animal models to understand its effects. For example, in research investigating neuroprotection, injection doses of SS-31 were 5 mg/kg and 10 mg/kg.Week 1: 10 units(1mg), 1x/day, 5 days/week· Weeks 2–5: 20 units (2mg), 1x/day, 5 days/week · Weeks 6–8: 30 units (3mg), 1x/day, 3 days/week · Weeks 9–12: 40 units ... In studies on cardiac health, a dose of 3 mg/kg/day for 10 weeks was utilized, with the SS-31 dose chosen based on previous optimizations in mouse models. Similarly, research into atherosclerosis in vivo involved treating mice with either 1 mg/kg SS-31 or 3 mg/kg.
It is important to note that there is limited data on proper dosing and protocol of administration for SS-31 (Elamipretide), underscoring the importance of professional guidance. However, the existing body of information suggests that SS-31 is generally well-tolerated across various dosing regimens and administration routes, with no evidence of tolerance development or diminishing therapeutic response reported.
While this overview provides insights into SS-31 peptide dosing, it is crucial to reiterate that all peptide therapies should be supervised by a trained healthcare professional2025年9月26日—The Mitochondrial ShieldSS-31is a targetedpeptidethat homes in on mitochondria, reducing oxidative stress and restoring cellular energy .... They can assess individual needs, monitor for potential SS-31 peptide side effects, and determine the most appropriate dosage considerations for the SS-31 peptide to ensure safety and efficacyI took it for6 weeks at a low dosewith the intent of reducing inflammation in my body from autoimmune related issues.. Experiences with SS-31 can vary, and some individuals, such as those with severe CFS, have reported responding to very low doses, like 0.SS-31 - The International Peptide Society100 mg - 0.500 mg (100mcg - 500mcg), suggesting that starting with low doses to determine response prior to escalating may be prudent. Ultimately, personalized medical advice is paramount when exploring the use of SS-31.
Join the newsletter to receive news, updates, new products and freebies in your inbox.